NO20076191L - Magnesiumsalter av HMG-COA reduktaseinhibitorer - Google Patents

Magnesiumsalter av HMG-COA reduktaseinhibitorer

Info

Publication number
NO20076191L
NO20076191L NO20076191A NO20076191A NO20076191L NO 20076191 L NO20076191 L NO 20076191L NO 20076191 A NO20076191 A NO 20076191A NO 20076191 A NO20076191 A NO 20076191A NO 20076191 L NO20076191 L NO 20076191L
Authority
NO
Norway
Prior art keywords
hmg
coa reductase
magnesium salts
reductase inhibitors
compositions
Prior art date
Application number
NO20076191A
Other languages
English (en)
Inventor
Yatendra Kumar
Swargam Sathyanarayana
Saridim Madhava Dileep Kumar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37308379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20076191(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of NO20076191L publication Critical patent/NO20076191L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Den foreliggende oppfinnelse angår magnesiumsalter av HMG-CoA-reduktaseinhibitorer, fremgangsmåte for fremstilling derav, farmasøytiske preparater derav og fremgangsmåter for å anvende preparatene i behandling av pattedyr som lider av hyperkolesterolemi.
NO20076191A 2005-05-03 2007-11-30 Magnesiumsalter av HMG-COA reduktaseinhibitorer NO20076191L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1108DE2005 2005-05-03
PCT/IB2006/051396 WO2006117761A2 (en) 2005-05-03 2006-05-03 Magnesium salts of hmg-coa reductase inhibitors

Publications (1)

Publication Number Publication Date
NO20076191L true NO20076191L (no) 2008-01-30

Family

ID=37308379

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076191A NO20076191L (no) 2005-05-03 2007-11-30 Magnesiumsalter av HMG-COA reduktaseinhibitorer

Country Status (9)

Country Link
US (1) US20100222405A1 (no)
EP (2) EP1879862B1 (no)
AT (1) ATE496025T1 (no)
DE (1) DE602006019710D1 (no)
DK (1) DK1879862T3 (no)
ES (1) ES2304911T3 (no)
NO (1) NO20076191L (no)
PT (1) PT1879862E (no)
WO (1) WO2006117761A2 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2304335T3 (es) 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
US20100168201A1 (en) * 2005-11-29 2010-07-01 Biocan Limited Polymorphs of [R-(R*, R*) ]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid Magnesium Salt (2:1)
WO2007099552A2 (en) * 2006-03-02 2007-09-07 Matrix Labaratories Ltd Novel crystalline form of atovastatin hemi-magnesium
SI22255A (sl) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
IS8587A (is) * 2006-12-27 2008-06-28 Actavis Group Hf. Atorvastatin lyfjasamsetning
WO2009063476A1 (en) * 2007-11-16 2009-05-22 Biocon Limited A crystalline form of atorvastatin hemi magnesium salt and a process thereof
EP2130819A3 (en) 2008-04-10 2009-12-23 Ranbaxy Laboratories Limited Crystalline forms of atorvastatin magnesium
WO2009157005A1 (en) * 2008-06-26 2009-12-30 Biocon Limited Crystalline forms of atorvastatin hemi-magnesium salt and a process thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
KR20080064908A (ko) * 2000-06-28 2008-07-09 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
OA12777A (en) * 2002-02-14 2006-07-06 Ranbaxy Lab Ltd Formulations of atorvastatin stabilized with alkali metal additions.
AU2005305460B2 (en) * 2004-11-22 2011-04-21 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
EP1833466A1 (en) * 2004-12-28 2007-09-19 Ranbaxy Laboratories Limited Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
EP1853249A2 (en) * 2005-02-10 2007-11-14 LifeCycle Pharma A/S A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor
ES2304335T3 (es) * 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
US20100168201A1 (en) * 2005-11-29 2010-07-01 Biocan Limited Polymorphs of [R-(R*, R*) ]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid Magnesium Salt (2:1)
WO2007099552A2 (en) * 2006-03-02 2007-09-07 Matrix Labaratories Ltd Novel crystalline form of atovastatin hemi-magnesium
SI22255A (sl) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
EP2016048A4 (en) * 2006-05-11 2010-06-23 Biocon Ltd CRYSTALLINE FORM B4 OF ATORVASTATIN MAGNESIUM AND METHOD THEREFOR
EP2130819A3 (en) * 2008-04-10 2009-12-23 Ranbaxy Laboratories Limited Crystalline forms of atorvastatin magnesium

Also Published As

Publication number Publication date
US20100222405A1 (en) 2010-09-02
PT1879862E (pt) 2011-04-19
DK1879862T3 (da) 2011-05-16
WO2006117761A2 (en) 2006-11-09
WO2006117761A3 (en) 2007-03-29
ES2304911T3 (es) 2011-05-30
ES2304911T1 (es) 2008-11-01
EP1879862B1 (en) 2011-01-19
DE602006019710D1 (de) 2011-03-03
EP1879862A2 (en) 2008-01-23
ATE496025T1 (de) 2011-02-15
EP2172452A1 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
NO20076191L (no) Magnesiumsalter av HMG-COA reduktaseinhibitorer
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
CY1117524T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20084435L (no) C-MET proteinkinaseinhibitorer
WO2008033562A3 (en) Kinase inhibitor compounds
NO20064852L (no) Azaindoler som er nyttige som inhibitorer av jak og andre proteinkinaser
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
TW200616953A (en) Indole, indazole or indoline derivatives
NO20074446L (no) DR5-antistoffer og anvendelser derav
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application